Literature DB >> 9459550

Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo.

H E Möller1, J Weglage, D Wiedermann, P Vermathen, U Bick, K Ullrich.   

Abstract

In vivo proton magnetic resonance spectroscopy was used to investigate intracerebral phenylalanine (Phe) concentrations in nine patients with classical phenylketonuria (PKU). The study included serial examinations (n = 31; plasma Phe levels: 0.47-2.24 mmol/l) of patients either receiving a Phe-restricted diet (200 mg Phe per day; four patients) or a diet rich in Phe (1000 mg Phe per day; three patients). No spectrum showed metabolic abnormalities besides elevated Phe. Difference spectroscopy yielded intracerebral Phe concentrations between 0.20 and 0.76 mmol/l. Regional variations between parieto-occipital periventricular brain, frontal brain, and cerebellum were not statistically significant. Data could be fitted assuming saturable Phe transport into the brain, based on a symmetric Michaelis-Menten model (characterized by an apparent Michaelis transport constant, K(t,app), and a maximum transport velocity, Tmax) and constant Phe consumption in the brain cells (described by a velocity Vmax). Non-linear least-squares fitting of the combined data from all patients yielded K(t,app) = 0.16 +/- 0.11 mmol/l and (Tmax / Vmax) = 9.0 +/- 4.1. Carrier saturation and competitive inhibition of the influx of other large neutral amino acids can be expected at plasma Phe levels usually found in PKU patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9459550     DOI: 10.1016/s0006-8993(97)01054-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

2.  Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.

Authors:  J Pietz; R Kreis; A Rupp; E Mayatepek; D Rating; C Boesch; H J Bremer
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  Large neutral amino acids in the treatment of phenylketonuria (PKU).

Authors:  R Matalon; K Michals-Matalon; G Bhatia; E Grechanina; P Novikov; J D McDonald; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2006-09-21       Impact factor: 4.982

4.  Phenylketonuria: brain phenylalanine concentrations relate inversely to cerebral protein synthesis.

Authors:  Martijn J de Groot; Paul E Sijens; Dirk-Jan Reijngoud; Anne M Paans; Francjan J van Spronsen
Journal:  J Cereb Blood Flow Metab       Date:  2014-10-29       Impact factor: 6.200

5.  Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria.

Authors:  V Leuzzi; M C Bianchi; M Tosetti; C L Carducci; C A Carducci; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

6.  Phenylalanine can be detected in brain tissue of healthy subjects by 1H magnetic resonance spectroscopy.

Authors:  J Pietz; T Lutz; K Zwygart; G F Hoffmann; F Ebinger; C Boesch; R Kreis
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

7.  Alanine prevents the reduction of pyruvate kinase activity in brain cortex of rats subjected to chemically induced hyperphenylalaninemia.

Authors:  Luciane Rosa Feksa; Andrea Renata Cornelio; Virginia Cielo Rech; Carlos Severo Dutra-Filho; Angela Terezinha Souza Wyse; Moacir Wajner; Clóvis Milton Duval Wannmacher
Journal:  Neurochem Res       Date:  2002-09       Impact factor: 3.996

8.  The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study.

Authors:  V Leuzzi; M Tosetti; D Montanaro; C Carducci; C Artiola; C Carducci; I Antonozzi; M Burroni; F Carnevale; F Chiarotti; T Popolizio; G M Giannatempo; V D'Alesio; T Scarabino
Journal:  J Inherit Metab Dis       Date:  2007-01-23       Impact factor: 4.750

9.  Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids.

Authors:  D Concolino; I Mascaro; M T Moricca; G Bonapace; K Matalon; J Trapasso; G Radhakrishnan; C Ferrara; R Matalon; P Strisciuglio
Journal:  Eur J Clin Nutr       Date:  2016-09-14       Impact factor: 4.016

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.